Form 4: Aadi Bioscience Executive Chairman Neil Desai Sells Shares

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on March 1 and March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• Neil Desai, the Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on March 1 and March 4, 2024.
• On March 1, 2024, Desai sold 27,036 shares at a weighted average price of $1.9687, with prices ranging from $1.93 to $1.995.
• On March 4, 2024, Desai sold 14,964 shares at a weighted average price of $2.0994, with prices ranging from $2.02 to $2.175.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 20, 2021, and replaced on December 1, 2022.
• After these transactions, Desai directly owns 1,426,507 shares and indirectly owns 639,698 shares through the Anishka Irrevocable 2016 Trust.
• Desai also holds shares through the Anishka Family Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports the sale of shares by an executive. The sales were pre-planned under a 10b5-1 trading plan, mitigating potential negative interpretations.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may react to the news of the Executive Chairman selling shares, although the pre-planned nature of the sales may lessen the impact.

Key Dates